Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity IMAGION BIOSYSTEMS LIMITED ABN 42 616 305 027 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Michael HARSH Date of last notice 26 June 2020 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) N/A Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 6 August 2020 No. of securities held prior to change i) 260,000 Shares ii) 60,000 Listed Options (exercisable at $0.03, expiring on 28 April 2023) Class i) Fully Paid Ordinary Shares (Shares) ii) Listed Options Number acquired i) Nil Shares ii) Nil Listed Options iii) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) iv) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) Number disposed Nil + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back i) N/A per Share ii) N/A Listed Options iii) Nil Consideration for Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) iv) Nil Consideration for Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) i) 260,000 Shares ii) 60,000 Listed Options (exercisable at $0.03, expiring on 28 April 2023) iii) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2021, expiring 1 May 2026) iv) 250,000 Unlisted Performance Options (exercisable at $0.028, vesting on 1 May 2022, expiring 1 May 2027) Unlisted Performance Options were issued as part of the Company’s EIP as outlined in the Notice of Annual General Meeting to Shareholders on the 19th July 2020 and approved by the shareholders at the Company’s 2020 AGM. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) Date of change N/A No. and class of securities to which interest related prior to change N/A N/A Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3